# MYELOPEROXIDASE (MPO) ASSAY

## A Sensitive Inflammatory Biomarker

Myeloperoxidase (MPO) is a hemoprotein present in leukocytes of blood circulation. It is well known that in published literature, elevated levels of plasma MPO is a sensitive indicator of inflammatory disorders. HPO is involved in the oxidation of lipids contained within LDL particles, and its reaction products including hydrogen peroxide are involved in the initiation of systemic inflammation. Diazyme's Latex Enhanced Immunoturbidimetric MPO Assay is accurate, cost effective and designed to work on validated general chemistry analyzers.

### DIAZYME MYELOPEROXIDASE (MPO) ASSAY ADVANTAGES

- The MPO assay has been designed to work on most modern high throughput general chemistry analyzers
- · Faster reporting and improved workflow for research laboratories
- Automated parameters available for a wide range of clinical instrumentation
- Liquid stable format requires no reagent preparation

### **REGULATORY STATUS**

USA: For Research Use Only


Œ

### AVAILABLE INSTRUMENT SPECIFIC PACKAGING

- Roche
  - Hitachi








**Dual Vial Liquid Stable** 



### **ASSAY SPECIFICATIONS**

Latex Enhanced Immunoturbidimetric Assay
<ul> <li>Plasma</li> <li>Lithium Heparin</li> <li>EDTA</li> </ul> Sample Volume 15 μL
N = 54 y-intercept = 35.4 pmol/L Slope = 1.01 R <sup>2</sup> = 0.98 Samples Ranged From: 31.4 ng/mL to 715.6 ng/mL
83 to 5000 pmol/L
12 ng/mL
5-Point Calibration

# Myeloperoxidase (MPO) Assay Procedure\*



\*Analyzer Dependent

For a list of validated parameters please contact Diazyme technical support at 858.455.4768 or email support@diazyme.com

- Nilsson L et al. (1988) Activation of inflammatory system during cardiopulmonary bypass. Scand J Thorac Cardovasc Surg. 22: 51-3
   Heinecke JW et al. (1999) Mechanisms of oxidative damage by myeloperoxidase in atherosclerosis and other inflammatory disorders. J Lab Clin Med 133: 321-5
- Podii'chak MD and Terletskaia LM (1988) Clinical value of determing myeloperoxidase and alkaline phosphatase activity of the leukocytes in patients with suppuractive inflammatory processes. Klin Khir 59-60
   4. G. Azzimondi G Re. et al (1997) Plasma lipoperoxidative markers in ischaemic stroke suggest brain embolism. European Journal of Emergency Medicine 4.5-9
- 5. Luigi M. B. et al. (1996) Intracellular Neutrophil Myoloperoxidase is reduced in unstable angina and acute myocardial infraction, but its reduction is not related ischemia. JACC Vol. 27, No.3: 611-6.
- Jessie Shih et al. (2008) Effect of collection tube type and preanalytical handling on myeloperoxidase concentrations. Clin. Chem. 54:6 1076–1079.
   Podrez EA, Schmitt D, Hoff HF et al.: Myeloperoxidase-generated reactive nitrogen species convert LDL into an atherogenic form in vitro. J. Clin. Invest. 103, 1547–1560 (1999).
- 8. Naruko T, Ueda M, Haze K et al.: Neutrophil infiltration of culprit lesions in acute coronary syndromes. Circulation 106, 2894–2900 (2002).

  9. Buffon A, Biasucci LM, Liuzzo G et al.: Widespread coronary inflammation in unstable angina. N. Engl. J. Med. 347, 5–12. (2002).
- Sugiyama S, Okada Y, Sukhova GK et al.: Macrophage myeloperoxidase regulation by granulocyte macrophage colony-stimulating factor in human atherosclerosis and implications in acute coronary syndromes. Am. J. Pathol. 158, 879–891 (2001).

### **ASSAY PRECISION**

The simple precision of the Diazyme MPO Immunoassay was evaluated. In the study, two levels of MPO controls containing 534 pmol/L (77ng/mL) and 3824 pmol/L (551 ng/mL) MPO respectively were tested with 15 duplicates in one run.

	Level 1: 534 pmol/L	Level 2: 3824 pmol/L
Number of Data Points	15	15
Mean (U/L)	534	3824
SD (U/L)	15	158
CV (%)	2.7%	4.1%

### **ASSAY INTERFERENCE**

The substances normally present in the plasma were tested. Less than 10% deviation was produced when tested up to the concentrations shown below:

Ascorbic Acid: 10 mM
Bilirubin, free: 40 mg/dL
Bilirubin, conjugated: 40 mg/dL
Hemoglobin: 200 mg/dL
Triglyceride: 270 mg/dL
Rheumatoid: 75 IU/mL

### **DIAZYME LABORATORIES, INC.**

12889 Gregg Court, Poway, CA 92064 PO Box 85608, San Diego, CA 92186 Tel: 858-455-4768 888-DIAZYME

www.diazyme.com sales@diazyme.com

### **DIAZYME EUROPE GMBH**

Zum Windkanal 21, 01109 Dresden, Deutschland Tel. +49 (0) 351 886 3300 Fax +49 (0) 351 886 3366 sales@diazyme.de

### SHANGHAI DIAZYME CO., LTD.

Room 201,1011 Halei Road, Zhangjiang Hi-tech Park Shanghai, 201203, People's Republic of China Tel: 086-21-51320668 Fax: 086-21-51320663 www.lanyuanbio.com service@lanyuanbio.com



DZ113 (07/2017)